CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

May 29, 2019

|

NEW YORK (GenomeWeb) – Researchers from the University of California, San Francisco used a genome-scale CRISPR interference (CRISPRi) functional genomics platform to systematically identify genetic interactions with a mutant form of KRAS called KRAS^G12C, and found combination therapies that target genes involved in its activity.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

To read the full story....

Breaking News

Puma's Neratinib sNDA Approved by FDA for HER2-Positive Metastatic Breast Cancer

iOnctura Doses First Patient in Phase I Study of Novel PI3K Inhibitor for Solid Tumors

Oncologie, Moffitt to Collaborate on Developing Targeted Treatment for Gastric and GI Cancers

GSK's sNDA for Ovarian Cancer Drug Zejula Accepted by FDA

Takeda's Alunbrig sNDA for ALK-Positive Non-Small Cell Lung Cancer Accepted by FDA

Genetic Testing Challenges in Oncology: Confusion Over Colon Cancer Syndromes Leads to Wrong Testing

Featured White Papers

What's Popular?

Epic EMR Users Begin Integrating Genomics Data for Clinical Decision Support

Follow-up Study Confirms Viability of PD-L1 as Biomarker for Pembrolizumab

Puma's Neratinib sNDA Approved by FDA for HER2-Positive Metastatic Breast Cancer

Genetic Testing Challenges in Oncology: Confusion Over Colon Cancer Syndromes Leads to Wrong Testing

Genentech Basket Trial Data Supports Genomic Profiling of Salivary Cancer Patients for Precision Treatment

Sponsorships